NCT05775432 Prognosis of Heart Transplanted Patients With Heart Failure
| NCT ID | NCT05775432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-04-23 |
| Primary Completion | 2042-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-04-23 with a primary completion date of 2042-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia. Several clinical studies have shown significant differences in the prognosis of heart transplantation patients with different etiologies, and post-transplantation complications are an important factor affecting patient survival, and there is still a lack of overall prognostic stratification and extensive clinical studies on risk factors after heart transplantation. Therefore, this study is intended to include patients who underwent heart transplantation for different etiologies of heart failure, collect clinical data and biological samples from patients, and use various techniques to deeply interpret the risk factors affecting the prognosis of heart transplantation patients and construct a prognostic prediction model to provide specific and individualized treatment ideas and theoretical basis for improving the survival rate of patients after heart transplantation.
Eligibility Criteria
Inclusion Criteria: * Patients with end-stage heart failure presented to our hospital who are evaluated by clinicians and ethically approved for heart transplantation * Individuals whose hearts are donated Exclusion Criteria: * Patients refuse to sign informed consent form
Contact & Investigator
Guoliang Li
PRINCIPAL INVESTIGATOR
First Affiliated Hospital Xi'an Jiaotong University
Frequently Asked Questions
Who can join the NCT05775432 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 80 Years, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05775432 currently recruiting?
Yes, NCT05775432 is actively recruiting participants. Contact the research team at liguoliang_med@163.com for enrollment information.
Where is the NCT05775432 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT05775432 clinical trial?
NCT05775432 is sponsored by First Affiliated Hospital Xi'an Jiaotong University. The principal investigator is Guoliang Li at First Affiliated Hospital Xi'an Jiaotong University. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.